NEW YORK, NY--(Marketwire - Oct 22, 2012) - Immunovative Inc. (OTCQB: [ IMUN ]) ("The Company") has today announced that the Company has been invited to present at the Deal Flow Conference 2012 ("the conference") at the Marriott Marquis Hotel, New York City (Times Square). The Company will present at 3:45 pm EDT on November 01, 2012. Those who will be attending the conference include: institutional investors, investment bankers, fund managers, analysts, and private investors. The Company is excited for the opportunity to increase its awareness in the investment community and establish relationships with additional institutional investors. 

PRESENTING ON BEHALF OF IMMUNOVATIVE INC.

1) Mr. Seth M. Shaw - President & CEO, Immunovative Inc.

2) Dr. Michael Har-Noy - Founder & Chief Executive Officer, Immunovative Therapies Ltd.

PLEASE CLICK ON BELOW LINK FOR DETAILS ON THE DEAL FLOW CONFERENCE 2012

[ http://www.dealflowmedia.com/conferences/dealflow_conference_2012/ ]

About Immunovative, Inc.:

On December 12th, 2011, Immunovative, Inc. ("IMUN") signed an exclusive License Agreement (the "License Agreement") with Immunovative Therapies, Ltd. ("ITL"). Under the terms of the License Agreement, IMUN has been granted an exclusive, worldwide license to commercialize any products covered under ITL's current issued and pending patent application portfolio, as well as the rights to any future patent applications, including improvements or modifications to the existing applications and any corresponding improvements or new versions of the existing products. Please visit IMUN's website at [ www.imun.com ]

About Immunovative Therapies, Ltd.:

Immunovative Therapies, Ltd. is an Israeli biopharmaceutical company that was founded in May 2004 with financial support from the Israeli Office of the Chief Scientist. ITL is a graduate of the Misgav Venture Accelerator, a member of the world-renowned Israeli technological incubator program. The company was the Misgav Venture Accelerator's candidate for the prize for the outstanding incubator project of 2006, awarded by the Office of the Chief Scientist. ITL specializes in the development of novel immunotherapy drug products that incorporate living immune cells as the active ingredients for treatment of cancer and infectious disease. Please visit ITL's website at: [ www.immunovative.co.il ]

DISCLAIMER:

Forward-Looking Statements: Except for statements of historical fact, this news release contains certain "forward-looking statements" as defined by the Private Securities Litigation Reform Act of 1995, including, without limitation expectations, beliefs, plans and objectives regarding the development, use and marketability of products. Such forward-looking statements are based on present circumstances and on IMUN's predictions with respect to events that have not occurred, that may not occur, or that may occur with different consequences and timing than those now assumed or anticipated. Such forward-looking statements involve known and unknown risks, uncertainties and other factors, and are not guarantees of future performance or results and involve risks and uncertainties that could cause actual events or results to differ materially from the events or results expressed or implied by such forward-looking statements. Such factors include general economic and business conditions, the ability to successfully develop and market products, consumer and business consumption habits, the ability to fund operations and other factors over which IMUN has little or no control. Such forward-looking statements are made only as of the date of this release, and IMUN assumes no obligation to update forward-looking statements to reflect subsequent events or circumstances. Readers should not place undue reliance on these forward-looking statements. Risks, uncertainties and other factors are discussed in documents filed from time to time by IMUN with the Securities and Exchange Commission.